How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Terry-Ann Burrell, insider at Beam Therapeutics

Terry-Ann Burrell Insider Information

Terry-Ann Burrell has served as our Chief Financial Officer since August 2019 and as our Chief Financial Officer and Treasurer since September 2019. From May 2008 to August 2019, Ms. Burrell worked at J.P. Morgan Securities LLC, where she most recently served as Managing Director. Ms. Burrell was responsible for deal execution across both mergers and acquisitions and capital markets. In her role, she advised biotechnology and pharmaceutical companies on strategic considerations, including mergers and acquisitions, initial public and secondary offerings and valuation analysis. Ms. Burrell currently serves on the board of directors of Recursion Pharma, a biotherapeutics company. Ms. Burrell holds a bachelor’s degree from Harvard College and an MBA from New York University’s Leonard N. Stern School of Business. Provided by Tagnifi.

What is Terry-Ann Burrell's net worth?

The estimated net worth of Terry-Ann Burrell is at least $1.35 million as of March 31st, 2022. Ms. Burrell owns 38,278 shares of Beam Therapeutics stock worth more than $1,347,003 as of May 22nd. This net worth estimate does not reflect any other investments that Ms. Burrell may own. Additionally, Ms. Burrell receives a salary of $683,750.00 as CFO at Beam Therapeutics. Learn More about Terry-Ann Burrell's net worth.

How old is Terry-Ann Burrell?

Ms. Burrell is currently 45 years old. There are 3 older executives and no younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics is Ms. Suzanne Fleming, Chief Accounting Officer, who is 61 years old. Learn More on Terry-Ann Burrell's age.

What is Terry-Ann Burrell's salary?

As the CFO of Beam Therapeutics Inc., Ms. Burrell earned a total compensation package of $683,752.00 in 2020. Ms. Burrell earned a salary of $420,000.00, non-equity compensation of $210,000.00, and other compensation of $53,752.00.There are 2 executives that earn more than Ms. Burrell. The highest earning executive at Beam Therapeutics is Mr. John M. Evans M.B.A., CEO & Director, who commands a salary of $906,770.00 per year. Learn More on Terry-Ann Burrell's salary.

How do I contact Terry-Ann Burrell?

The corporate mailing address for Ms. Burrell and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at [email protected] Learn More on Terry-Ann Burrell's contact information.

Has Terry-Ann Burrell been buying or selling shares of Beam Therapeutics?

Terry-Ann Burrell has not been actively trading shares of Beam Therapeutics during the last ninety days. As an example of a recent trade by , 0 shares of the stock in a transaction dated Sunday, May 22nd. Learn More on Terry-Ann Burrell's trading history.

Who are Beam Therapeutics' active insiders?

Beam Therapeutics' insider roster includes Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), and John Evans (CEO). Learn More on Beam Therapeutics' active insiders.

Are insiders buying or selling shares of Beam Therapeutics?

In the last twelve months, insiders at the sold shares 14 times. They sold a total of 325,416 shares worth more than $30,403,008.43. The most recent insider tranaction occured on April, 28th when CEO John M Evans sold 30,000 shares worth more than $1,139,400.00. Insiders at Beam Therapeutics own 0.7 % of the company. Learn More about insider trades at Beam Therapeutics.

Information on this page was last updated on 4/28/2022.

Terry-Ann Burrell Insider Trading History at Beam Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/31/2022Sell1,787$59.11$105,629.5738,278View SEC Filing Icon  
6/30/2021Sell30,000$122.00$3,660,000.00View SEC Filing Icon  
6/28/2021Sell45,000$107.69$4,846,050.0069,809View SEC Filing Icon  
See Full Table

Terry-Ann Burrell Buying and Selling Activity at Beam Therapeutics

This chart shows Terry-Ann Burrell's buying and selling at Beam Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beam Therapeutics Company Overview

Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $35.19
Low: $31.58
High: $35.86

50 Day Range

MA: $47.32
Low: $29.96
High: $63.11

2 Week Range

Now: $35.19
Low: $27.77
High: $138.52

Volume

1,198,405 shs

Average Volume

1,507,074 shs

Market Capitalization

$2.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59
How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.